Polymyalgia Rheumatica to Remission – A Case Study

Case Study: Severe Polymyalgia Rheumatica to Remission – This is a case study of a 69 year old man who had an onset of pain 10 years prior that eventually encompassed the whole body with debilitating pain. The patient had further issues other than pain; details in report. This patient with the help of Dr. Patrick Lynch has reached and remained in remission for 5 years after 10 months of treatment. The patient gradually made improvements with a decrease in symptoms at every 5 week check up and reached the point of being symptom free after 7 months. The patient has not had the need for further treatment since January of 2022. 

Abstract

Background: Polymyalgia rheumatica (PMR) is an inflammatory condition presenting with symptoms of pain and stiffness in the shoulder and pelvic girdles, often with elevated inflammatory markers such as ESR and CRP. PMR most commonly affects adults over 50. Exploration of the cause of PMR is typically not explored. 

Objective: To describe a case of a 60+ year-old male with a prior PMR diagnosis and severe, multi-system symptoms; and to demonstrate the Chinese medicine integrative program of 10 months, with symptom remission.

Methods: Dietary modifications with a supplement/herbal protocol, including s-acetyl glutathione and full spectrum antimicrobial Chinese medicine herbal formulas with systemic properties, with periodic rotation of herbal formula formulations. Progress tracking with check-ins every 5 weeks. 

Results: Measurable improvements during each 5 week check in, with broad symptom resolution by month 7 with care through 10 months to support remission. Follow-up every year since treatment; the patient has no symptom recurrence.

Clinical note: This is an observational case report. It does not establish causation in all cases, does not replace medical evaluation, and outcomes may not be generalizable.

---

Background and Patient History

Case Study: Severe Polymyalgia Rheumatica to Remission

A male in his 60s had a prior diagnosis of polymyalgia rheumatica, reporting approximately 10years of progressive, debilitating symptoms. Prior to symptom onset, he described himself as active and healthy without chronic illness.

He reported symptom onset following prolonged exposure to an indoor environment that “smelled funny,” later associated with water intrusion and visible mold. He reported living near a canal for many years with frequent mosquito exposure, describing hundreds of mosquito bites over time. Given the combination of chronic inflammatory symptoms and environmental exposures, a working clinical consideration included potential contributions from environmental biotoxins and/or chronic infectious triggers, alongside inflammatory and immune dysregulation.

---

Initial Presentation 

Case Study: Severe Polymyalgia Rheumatica to Remission – First visit

At intake, the patient was visibly unwell with marked functional impairment. He reported severe global pain, sleep disruption, and prominent neurocognitive and autonomic-type symptoms.

Primary Symptom Cluster: Pain, Stiffness, and Functional Decline

• Pain began in the shoulders, migrated to the hips, and progressed to widespread pain involving:

  • feet/ankles/calves/thighs/knees/hips

  • ribs, spine, neck (sides and posterior)

  • wrists/hands with reduced grip strength (unable to make a fist)

• Alternating numbness and burning pain on the soles of the feet

• Severe cramping (calves, hands, ribs/chest)

• Balance impairment with frequent falls; walking required constant attention

• Jaw pain with difficulty chewing

• “Electrical” shooting pains in back/hip

• Global weakness and perceived muscle atrophy

• Sleep limited to ~3 hours/night, non-restorative

• Drenching night sweats and nightmares

• Intermittent severe gout flares

Additional Symptoms – Multi-System

• Chronic sinusitis, chronic cough, persistent throat clearing

• Episodes of throat tightness/“choking” sensation and intermittent difficulty swallowing

• Brain fog, short-term memory issues

• Severe anxiety with depressive episodes

---

Prior Conventional Evaluation and Treatment

The patient reported evaluation by a clinician specializing in autoimmune disorders. Lab findings as recalled by the patient included:

• Elevated ESR and CRP

• Low white blood cell count

• Elevated cholesterol and hematocrit (per report)

Based on symptoms and inflammation markers, he carried a diagnosis of polymyalgia rheumatica and was prescribed prednisone. He reported minimal benefit from prednisone.

Clinical context: Elevated ESR/CRP support systemic inflammation but are not specific. A low WBC can occur for many reasons and does not independently confirm chronic infection. PMR is a clinical diagnosis supported by labs and response to therapy; however, overlapping conditions can mimic PMR, especially when neuropathic and multi-system symptoms are prominent.

---

Integrative Clinical Reasoning – A Holistic Approach

Given the severity, chronicity, and breadth of symptoms—plus a history of mold exposure and heavy vector exposure—the working hypothesis emphasized:

1. Chronic inflammatory activation (supported by ESR/CRP history and symptom pattern)

2. Possible upstream contributors such as environmental exposures (mold), immune triggers, and impaired inflammatory resolution

3. Specific symptom presentation leading to malarial type pathogen likely from mosquito vectors. 

4. The need for a stepwise approach to reduce symptom burden while supporting detoxification capacity and physiologic resilience

This clinical approach was informed by symptom pattern recognition used in integrative chronic illness frameworks (including Multiple Infectious Disease Syndrome (MSIDS), while acknowledging that such frameworks do not replace conventional diagnostic confirmation, but can enhance reasoning for it.

---

Treatment Approach – 9 – 10 Months

Case Study: Severe Polymyalgia Rheumatica to Remission – Phase 1

Care occurred from approximately March 2020 through January 2021. The program emphasized staged treatment escalation to maximize treatment tolerability and reduce the risk of symptom flares. Appointments are scheduled every 5 weeks to track progress and modify treatment as needed. Patient is provided Dr. Lynch’s cell phone to be able to ask questions at any time. this best assures progress at the 5 week mark.

Phase 1

Weeks 1–5: Beginning Treatment – Initial Structure

• Dietary modifications (anti-inflammatory focus) – Decrease pathogenic motility and proliferation decreases immune responsiveness which decreases symptoms and enables treatment to knock back pathogen faster than they can reproduce. 

• S-acetyl glutathione 400 mg twice daily for 7 days initially, then continued for the duration of treatment. 

• Initiation of a full-spectrum botanical antimicrobial formulas (Spiro-Clear I and Intra-Cell I) using a cautious titration to reach target dosing of one formula at a time. First Spiro-Clear, then included Intra-Cell once the patient reached a full dose of Spiro-Clear. 

• 1 month of intranasal antimicrobial support, x3 daily. (30ppm colloidal silver spray) with the intention to eradicate mold spores lodged in the sinuses with the intention to prevent daily reinfection from swallowing post nasal drip from chronic sinusitis. 

5 Week Outcome: The patient initially felt he was “not better,” but structured symptom review showed meaningful changes:

• Anxiety resolved

• Improved sleep

• Reduced neck pain

• Decreased sinus symptoms

• Night sweats resolved

• Early return of sensation to hands/feet

• No new or worsening symptoms 

---

Phase 2

Weeks 6–10: Broader Coverage

Case Study: Severe Polymyalgia Rheumatica to Remission – Phase 2

• Continues supplemental and herbal therapy support with dietary modifications – S-acetyl glutathione, Spiro-Clear, Intra-Cell, other anti-microbial support. 

• Continues concurrent use of full doses twice per day of Spiro-Clear I + Intra-Cell I once tolerated. These two formulas are used for aggressive full spectrum antimicrobial support. In this patient’s case, the three clinically dominant diagnosed pathogens are mold with babesia and bartonella. Babesia and bartonella being malarial (mosquito-vector-born) pathogens.

10 Week Outcome: Continued symptom improvement, including:

• Less cramping

• Electrical sharp shooting pains – 50% improvement

• Swallowing/throat tightness gone

• Neck pain improvement by 50%

• Burning feet improvement by 50%

• Brain fog and memory improvement

• Increased energy

The patient noted that without structured comparison to baseline, progress felt slow—highlighting the value of 5 week standardized symptom tracking.

---

Phase 3

Months 3–5: Rotation and Deeper Targets

Case Study: Severe Polymyalgia Rheumatica to Remission – Phase 3

• Continues supplemental and herbal therapy support with dietary modifications – S-acetyl glutathione, Spiro-Clear, Intra-Cell, other anti-microbial support. 

• Rotation from Intra-Cell I to Intra-Cell II to vary botanical constituents. This rotation offsets specific pathogenic malarial resistance can develops within 7 weeks on average. 

• At 12 weeks, the patient felt 70% better across the board in regard to overall symptom decrease with increased energy. Treatment aggressive work synergistically with the herbal formulas to increase aggressiveness and assist with internal antimicrobial tissue saturation. Increase die-off reactions were noted immediately after increasing aggressiveness with increased fatigue and headaches that were ameliorated with 1tsp of bentonite clay mixed with a cup of warm water at the onset of headache. 

• At 20 weeks, after patient felt die-off symptoms leveling off from increased aggressiveness from increased antimicrobial support, there was a rotation from formulas Spiro-Clear I to Spiro-Clear II on Month 5. Spiro-Clear II is used for the intention to target deeper tissues, such as cartilage, tendon, disk, bursa, as well to assist in breaking down biofilms and cysts where pathogens tend to hide and be dormant. Penetrating to clean up dormant pathogen best prevents internal re-infection. Spiro-Clear II will now be used for 5 months with Intra-Cell I and II rotations every 7 weeks with other antimicrobial support. 

Notable event: Around week 10–12, the patient had a short-lived symptom flare (fatigue, aches, headaches, anxiety, sadness, depression,) lasting 5 days, followed by a clear improvement. This was considered a Herxheimer reaction.

20 Week Outcome:

• Marked reduction in widespread pain

• Anxiety and depressive episodes resolved

• Improved cognition

• Neck mobility improved 75%

• Night sweats and nightmares absent

• Cramping resolved

• Respiratory and sinus symptoms improved substantially

• Increased energy and overall feeling of improved health

Residual issues at that stage included partial persistent numbness in hands/feet and lingering hip/neck discomfort.

---

Phase 4

Months 5-10: Consolidation and Remission Support

Case Study: Severe Polymyalgia Rheumatica to Remission – Phase 4

• Continues supplemental and herbal therapy support with dietary modifications – S-acetyl glutathione, Spiro-Clear II (cyst/biofilm support), Intra-Cell, other anti-microbial support. 

• Addition of vascular-support nutrients (e.g., hesperidin) later in care, when symptom stability improved

• Final phase included a customized Chinese bulk herbal tea formulation, luo mai penetrating. This formula is used during Month 10 only, when the patient has reached a state of remission. One last dig to the most aggresive herbs to break down cysts and biofilms and target deep, hard to reach areas in the body, known in Chinese medicine as the luo mai. 

Reported outcomes:

• Intermittent 5 minute pain episodes in different areas of the body after taking cyst/biofilm formula during months 6–7 that resolved quickly – Hypothesis: This can happen when cysts are opened up and pathogen is neutralized in the area of short pain episodes. 

• By months 8–9, no report of treatment reactions

• By month 7, patient reports being symptom-free

• By month 9–10, patient remains symptom-free and discharged from active care with a prevention plan

Functionally, he returned to demanding activities (e.g., physical labor) that had been impossible prior to treatment.

---

Follow-Up and Current Status 

Post-treatment follow-up:

• Ongoing strength recovery – Herbal therapy to keep testosterone and IGF-1 levels in the high normal range to assist with strength and regeneration. 

• No return of prior symptoms since 2021. It is now January 2026.

• Above all, Improvement overall quality of life. 

---

Key Takeaways for Clinicians and Patients 

• Track symptoms systematically. Perceived progress can lag behind measurable improvement without structured review.

• PMR labels can overlap with broader inflammatory syndromes. Prominent neuropathic symptoms, autonomic-type symptoms, mental health symptoms, as well multi-system involvement that warrant careful evaluation and differential diagnosis.

• Staged protocols may improve tolerability. Gradual titration and rotation strategies were emphasized to reduce symptom flares, offset pathogenic resistance and enable the patient to gradually feel better month by month. 

• Remission support matters. Making sure the patient’s hormones are maximized at the end of treatment to assist quality of life and regeneration. 

---

Medical Disclaimer (E-E-A-T and Safety)

This case study reflects the experience of one patient and is provided for educational purposes. It does not prove that any intervention treats or cures polymyalgia rheumatica or any disease. Patients with suspected PMR should be evaluated by a qualified clinician —particularly to rule out urgent related conditions (such as giant cell arteritis) and other causes of systemic inflammation, neuropathy, and functional decline. Do not start, stop, or combine medications or supplements without medical supervision. This is not intended to be an instructional overview how to clean up the body from MSIDS. Everyone is different and should be supported clinically for their own presentation.

© Dr. Patrick Lynch – January, 2026